Privacy Policy

Effective date: February 06, 2020
Last updated: October 04, 2021

VICO Therapeutics. (“us”, “we”, or “our”) operates the https://vicotx.com/ website (the “Service”).

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you contact us, use our Service, other services and activities and the choices you have associated with that data.

Information Collection And Use visiting the website

We collect several different types of information for various purposes to provide and improve our Service to you. By using the Service, you agree to the collection and use of information in accordance with this policy.

The entity responsible for the processing of personal data: Vico Therapeutics B.V. established at BioScience Park BioPartner Building 1, J.H. Oortweg 21, 2333 CH Leiden, Chamber of Commerce number 75852748.

 

Types of Data Collected

Personal Data

While using our Service, we may collect certain personally identifiable information that can be used to identify you (“Personal Data”). Personally identifiable information may include, but is not limited to:

  • IP Address (we mask and anonymize every IP Address before storing)
  • Cookies and Usage Data

Sometimes we may collect personal data for the purpose of communicating with you. This data may include, but is not limited to:

  • Email address
  • First name and last name
  • Phone number
  • Address, State, Province, ZIP/Postal code, City

Usage Data

We may also collect information how the Service is accessed and used (“Usage Data”). This Usage Data may include information such as your computer’s Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Service that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

How we use your personal data

Vico Therapeutics uses the collected data for various purposes:

  • To provide and maintain the Service
  • To provide analysis or valuable information so that we can improve the Service
  • To monitor the usage of the Service
  • To detect, prevent and address technical issues

Sometimes we may collect personal data for the purpose of communicating with you.

If you contact us and choose to provide personally identifiable information such as your name, address, telephone number or email address, we will utilize it for the purpose for which you submitted it to us, such as to respond to your inquiry or to provide you with the information you have requested. By voluntarily providing us with your personal data, you are consenting to our use of it in accordance with this Privacy Policy.

What is the legal basis for our use of your personal data?

Vico Therapeutics uses the collected data for various purposes:

  • When you are an online visitor, we use your consent to use your online behaviour.
  • When you contact us, we use your consent to use contact details.

Your rights

You have certain rights regarding your personal data we hold about you, subject to European data protection laws. These are:

  • Right to access information about how we Process your Personal Data.
  • Right to rectification of inaccurate Personal Data concerning you.
  • Right to erasure (to be forgotten) of Personal Data relating to you.
  • Right to restriction of processing (i.e. data is blocked for normal Processing, but not deleted).
  • Right to withdraw your Consent at any time, when the Processing is based on your Consent.
  • Right to a notification regarding rectification or erasure of personal data, or restriction of Processing.
  • Right to data
  • Right to object to the processing of Personal Data based on our legitimate interests.
  • Right not to be subject to a decision based solely on automated processing (i.e. right to a “human intervention”).

If you wish to exercise any of your rights listed above, please contact us using the information in the “Contact” section at the end of this Privacy Policy. We will respond to your request within 30 days of receipt of such a request. If we are unable to honour your request we will inform you of the reasons why.

If you believe that our processing of your Personal Data violates data protection laws, you have a legal right to lodge a complaint with the Data Protection Authority. In the Netherlands, this is the Autoriteit Persoonsgegevens.

Retention

We will retain your personal data for as long as needed to fulfil the purposes for which we collected it, unless a longer retention period is required or permitted by applicable law. When the personal data is no longer necessary for the original processing purpose and there are no further legal requirements, we will delete your personal data.

International Transfer Of Data

Your information, including Personal Data, may be transferred to — and maintained on — computers located outside of your state, province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Netherlands and choose to provide information to us, please note that we transfer the data, including Personal Data, to the Netherlands and process it there.

Vico Therapeutics will take all steps reasonably necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your Personal Data will take place to an organization or a country outside the European Economic Area unless there are adequate controls in place including the security of your data and other personal information.

Security Of Data

VICO takes appropriate technical and organizational measures to ensure that the personal data we process is protected against unauthorized access, use, destruction, modification or disclosure in accordance with applicable laws and regulations.

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

How we may share your personal data

VICO Therapeutics may disclose your Personal Data in the good faith belief that such action is necessary to:

  • To comply with a legal obligation
  • To protect and defend the rights or property of VICO Therapeutics
  • To prevent or investigate possible wrongdoing in connection with the Service
  • To protect the personal safety of users of the Service or the public
  • To protect against legal liability

We may employ third party companies and individuals to facilitate our Service (“Service Providers”), to provide the Service on our behalf, to perform Service-related services or to assist us in analyzing how our Service is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Service.

  • Google Analytics
  • Google Tag Manager (does not gather data on its own, used for implementing Google Analytics tracking)

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

We store data regarding website traffic using Google Analytics. However Google Analytics will not share your data with other third parties using the platform. Only Vico Therapeutics has access to this data for purposes of tracking and reporting website traffic.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page: https://policies.google.com/privacy?hl=en

We will never sell your information to another entity unless VICO or parts of it are sold.

 

Links To Other Sites

Our Service may contain links to other sites that are not operated by us. If you click on a third party link, you will be directed to that third party’s site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third party sites or services.

 

Children’s Privacy

Our Service does not address anyone under the age of 18 (“Children”).

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

 

Changes To This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the “effective date” at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact us:

VICO Therapeutics B.V. BioScience Park
BioPartner Building 1,
J.H. Oortweg 21,
2333 CH Leiden.

By email: info@vicotx.com

Scroll to Top
Leadership

Leadership

Prarthana Khanna, PhD

Vice President, Corporate Business Development and Strategy

Linkedin icon

Prarthana joins us most recently from Eli Lilly where she led business development transactions across the enterprise, including but not limited to M&A, in-licensing, out-licensing, and equity investments. Prior to Lilly, Prarthana helped establish the business development function at Akouos and was part of the deal team for the Lilly’s acquisition of the company.

Prarthana obtained a B.Sc. in Genetics from the University of Western Australia in Perth, followed by a PhD in Genetics in David Walt’s lab at the Tufts University School of Medicine in Boston.

After completing her B.Sc., Prarthana worked as a Research Technologist at the Mass General Institute for Neurodegenerative Disease (MIND) where she conducted research on the Huntington’s Disease Biomarkers Program and conducted pre-clinical research with Novartis on therapeutic agents for Huntington’s Disease. During her PhD, Prarthana also worked at the Tufts technology transfer o4ce. After completing her PhD, Prarthana worked as a Senior BD Manager at the Harvard University O4ce of Technology Development, guiding Harvard faculty, post-docs, and grad students to commercialize their research. In this capacity, she negotiated licenses, options, and sponsored research agreements. After Harvard, Prarthana was at WuXi Biologics where she was the Head of Business Development and Licensing for North America and Europe and responsible for out-licensing WuXi Biologics’ proprietary platforms and antibodies.

Board of Directors

Board of Directors

Catello Somma
(Board Observer) Seroba Life Sciences
Linkedin icon

Catello Somma is a Partner at Seroba. He has a background in venture capital and clinical development, with a focus on the biotechnology and medical device industries. Prior to joining the firm in 2024, Catello was at TVM Capital (Munich), involved across different strategies for both biotech and medtech. Before starting a career in venture capital, Catello co-founded Clavius Pharmaceuticals, developing therapeutics for oncology and autoimmune diseases.
He started his career in 2009 working for different CROs and biotech companies between Italy and Switzerland.

Board of Directors

Board of Directors

Jeroen Vangindertael, PhD

Ackerman’s van Haaren
Linkedin icon

Dr. Vangindertael is an investment manager at Ackermans & van Haaren since 2020. Before that he was active at BNP Paribas Fortis Corporate banking in Life Sciences financing through debt and within their Private Equity department where he did both direct investments and fund-of-fund management of their Life Sciences VC portfolio. Jeroen holds a Master and a PhD degree in Biochemistry and Biotechnology from the KULeuven.

Board of Directors

Board of Directors

Micah Mackison

CEO, Vico Therapeutics

Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.

Board of Directors

Board of Directors

Felice Verduyn-Van Weegen

EQT Life Sciences

Linkedin icon

Felice Verduyn-Van Weegen is an Investment Manager at LSP and has been with the company since early 2015. Felice serves on the Boards of AM-pharma, Alize 3 pharma, Pharvaris (observer) and OxThera (observer). Prior to joining LSP, Felice was a consultant at McKinsey & Company with a primary focus on healthcare. Before McKinsey, she was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School.

Felice previously worked at the department of Biological Psychology at the VU University in Amsterdam and has authored numerousscientific articles in prestigious journals.

Felice was awarded a Bachelor’s degree in biological psychology and a Master’s degree in neuroscience from the VU University, Amsterdam. In addition, she was awarded an MBA from Columbia Business School.

Board of Directors

Board of Directors

Martijn Kleijwegt
EQT Life Sciences
Linkedin icon

Martijn Kleijwegt founded LSP in 1998 and currently serves as Managing Partner and co-owner of the firm where he is responsible for investing in unlisted securities and the general management of the firm. Prior to establishing LSP, Martijn ran another investment firm where he was responsible for investments in the healthcare sector.

As one of Europe’s most experienced healthcare investors, Martijn brings over 30 years of hands-on finance and investment experience to the LSP team. He has also been appointed a Director of numerous companies, all of which he helped to grow and flourish. Among others, Martijn currently serves as a Director of Kiadis Pharma, Orphazyme AS, OxThera AB, Pharvaris BV and Eloxx Pharmaceuticals.

Board of Directors

Board of Directors

Remi Droller
Kurma Partners
Linkedin icon

Rémi Droller serves as managing partner of Kurma Partners SA and member of the board of directors of Dyncaure SAS, ImCheck Therapeutics SAS, Orphazyme A/S, OxThera AB, AM Pharma BV, Flamingo Therapeutics BV and Pharvaris BV. Remi started at CDC Innovation from 2000 to 2003, later joining AGF Private Equity (now Idinvest Partners) where he developed the investment activity in the life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen) Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin) Vivacta (acquired by Novartis), IntegraGen (listed on Alternext) Onxeo (listed on Euronext).

Rémi holds a master’s degree in molecular biology from Pierre and Marie Curie University in Paris and a Master’s degree in finance and management of innovation from AgroParisTech.

Board of Directors

Board of Directors

Josh Mandel-Brehm

(Co-Founder) CAMP4 Therapeutics

Linkedin icon

Josh Mandel-Brehm is President and Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners.
Josh previously held key business development and operations leadership roles at leading biotech companies. Most recently he served at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise and overseeing seminal investments to enter the gene therapy and ophthalmology field. Prior to Biogen, Josh held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.

Josh earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Board of Directors

Board of Directors

Klaus Breiner, PhD

Pureos Bioventures
Linkedin icon

Klaus Breiner is a founding and managing partner of Pureos and has been a venture capital investor since 2001, involved with life science companies across different regions, stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Klaus has invested in numerous bio-pharmaceutical companies including AM-Pharma, Alpex Pharma, Cadence Pharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics and Vaximm. Prior to venture capital, Klaus was a researcher at ETH Zurich and a business consultant at Booz Allen & Hamilton.

Klaus holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg (ZMBH).

Board of Directors

Board of Directors

Amy Schulman
Polaris Partners
Linkedin icon

Amy Shulman is a healthcare investor and Managing Partner at Polaris Partners and LSPIF.
She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. Amy also represents Polaris as a director of Cyclerion (NASDAQ: CYCN), Dewpoint Therapeutics, Kallyope, Volastra, Thirty Madison and ByHeart. Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also co-founded the LS Polaris Innovation Fund which was formed in 2017.

Prior to joining Polaris, Amy was the general counsel of Pfizer, president of Pfizer Nutrition and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after its sale, Amy also became the president of Pfizer Consumer Healthcare.
She has received numerous awards including Xconomy’s 2017 Newcomer Award, Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, and Fortune Magazine’s 2013 50 Most Powerful Women in Business. She is a Senior Lecturer at Harvard Business School and serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital.  

Amy is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.

Board of Directors

Board of Directors

Anders Hinsby, PhD

(Independent) Muna Therapeutics
Linkedin icon

Anders Hinsby has more than 15 years of experience as a biotech entrepreneur, executive and investor. Currently, he is the CEO of Muna Therapeutics and works as entrepreneur-in-residence with Novo Seeds/Biorigin. Anders co-founded and served as CEO of Orphazyme A/S from 2009 to 2019 and led the company’s journey from University spin-out to a late-stage biopharmaceuticals company with a focus on rare diseases. In 2017, Anders led Orphazyme’s IPO on NASDAQ Copenhagen, raising 90 MUSD. Previously, he was a Principal and later Partner in BankInvest Biomedical Venture, a Danish life-science dedicated venture capital fund. He currently serves on the Boards of Intomics A/S a Danish Biotech.

Anders has a Ph.D. in Medicine from the University of Copenhagen.

Board of Directors

Board of Directors

Luc Dochez, PhD

(Chair and Founder) Droia Ventures

Linkedin icon

Luc Dochez is the Chairman and co-founder of Vico Therapeutics. He has been a Managing Partner at Droia Ventures since December 2018. Previously, Luc was Chief Executive Officer of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He also served as Chief Business Officer and Senior Vice President of Business Development at Prosensa Holdings until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, he served as Vice President of Business Development at TiGenix, Director of Business Development at Methexis Genomics and a consultant at Arthur D. Little.

Luc holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). Luc also serves on the Board of Directors of Erytech SA and is an advisor to EverImmune SA and QBIC II.

Board of Directors

Board of Directors

Name Name

Job Title

Illo assumenda recusandae quidem similique et consectetur voluptatem dolores adipisci harum sunt laboriosam. Dicta repudiandae beatae ipsa esse eligendi perferendis ex corporis voluptatum doloribus.

Leadership

Leadership

Scott Schobel, MD

Chief Medical Officer
Linkedin icon

As Chief Medical Officer, Dr. Scott Schobel is responsible for clinical development programs at VICO including the lead asset VO659, an allele-preferential ASO targeting CAG repeat expansion diseases.  He brings extensive experience in neurological drug development, particularly in Huntington’s disease.

Previously, Scott held several leadership positions at Roche. As Group Medical Director and most recently Clinical Science Leader, he pioneered the development of clinical endpoints in Huntington’s disease research. He co-chaired a task force that generated a new research-based disease staging framework for Huntington’s disease based on underlying biology. He also clinically led the first ever huntingtin-lowering therapy Phase 3 program with tominersen. Prior to Roche, Scott was an assistant professor of clinical psychiatry at Columbia University Medical Center where he studiedying hippocampal dysfunction across neurological and psychiatric diseases using a cross-species neuroimaging approach. He also served as medical director of Columbia University Medical Center’s Center of Prevention and Evaluation (COPE), a clinical service dedicated to the treatment and longitudinal study of teenagers and young adults at high risk for psychotic disorders.

Scott earned a BA in Japanese from the University of Minnesota, an MD from the University of North Carolina, and an M.S. from Columbia University.

Leadership

Leadership

Nicole Datson, PhD
Chief Scientific Officer
Linkedin icon

Dr. Nicole Datson serves as Chief Scientific Officer of VICO, where she is responsible for discovery and non-clinical drug development. With more than twenty years of experience in preclinical research in both academia and industry, Nicole brings a strong background in molecular neuroscience to her position. Prior to joining VICO, she served as Senior Director Drug Discovery and Early Preclinical Development at BioMarin Nederland B.V.. Previously, Nicole served as head of preclinical development at Prosensa Therapeutics B.V., developing antisense oligonucleotide-based therapies.

An internationally recognized expert, Nicole was a member of the international Huntington’s Disease Collaborative Research Group that cloned the gene for Huntington’s disease.
She obtained her PhD in molecular genetics from Leiden University, The Netherlands and held research staff positions as assistant professor at the Department of Medical Pharmacology and Human Genetics at Leiden University and Leiden University Medical Centre (LUMC). During her academic career, Nicole obtained several prestigious research grants and headed a research group in the field of molecular neuroscience where she focused on the identification of genes and pathways controlled by stress hormones in the brain as potential drug targets for treatment of stress-related brain disorders. She is the author of over 70 publications in peer-reviewed scientific journals in the field of molecular genetics, molecular biology and molecular neuroscience and RNA modulation.

Leadership

Leadership

Name Name

Job Title

Illo assumenda recusandae quidem similique et consectetur voluptatem dolores adipisci harum sunt laboriosam. Dicta repudiandae beatae ipsa esse eligendi perferendis ex corporis voluptatum doloribus.

Leadership

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.